Drug Topics
APRIL 22, 2024
According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.
Pharmacy Times
APRIL 22, 2024
Optical glucose sensing techniques have been reported, but they require complex optical instrumentations found in laboratories, so feasibility for patient use has been challenging.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 22, 2024
The Supreme Court decision to overturn Roe v. Wade has transformed not just abortion access but maternal health care across the United States, causing physicians in states with restrictive laws to shift treatment of conditions including ectopic pregnancy and miscarriage. The full scale of the impact, though, has been obscured in a polarized political climate where physicians are often afraid to speak out, or are blocked by their hospitals from talking about their experiences post-Dobbs.
Drug Topics
APRIL 22, 2024
Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 22, 2024
The ambitious idea of using CRISPR to cure genetic diseases before birth is one step closer to reality. Scientists reported on Monday that they used a form of the technology known as “ base editing ” to alter the DNA of laboratory monkeys in the womb, substantially reducing the levels of a toxic protein that causes a fatal liver disease before the animals had even been born.
Fierce Healthcare
APRIL 22, 2024
The Centers for Medicare & Medicaid Services is hoping to improve Medicaid enrollees’ access to care through a final rule that better compensates caregiving roles. | CMS released a series of final rules Monday, including Medicaid access regulations that some groups worry will cause providers to close.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
APRIL 22, 2024
Simple HealthKit is bringing chronic condition diagnostics to front porches across the country via a new partnership with Amazon. | Consumers can now buy Simple HealthKit’s at-home tests for diabetes (HbA1c), respiratory wellness and sexual wellness and have it shipped to their door through Amazon.
STAT
APRIL 22, 2024
Discontent among Mass General Brigham doctors had been at a slow burn for years. But when an unexpected announcement from the chief executive titled “A message about our future” popped into inboxes one morning last month, that frustration seemed to fully ignite. Mass General Brigham, a dominant force in Boston medicine, was launching the latest and perhaps most contentious step in its ongoing effort to merge its two flagship Harvard-affiliated medical centers: combine all departmen
Fierce Healthcare
APRIL 22, 2024
The $4 trillion healthcare industry is a data-rich sector, and every healthcare player is trying to find a way to use information to drive better decisions, whether in the clinic or the boardroom.< | The $4 trillion healthcare industry is a data-rich sector, and every healthcare player is trying to find a way to use information to drive better decisions, whether in the clinic or the boardroom.
STAT
APRIL 22, 2024
Makena, once the only available treatment to prevent preterm birth, has had its share of controversy. A yearslong debate over the drug’s effectiveness led the Food and Drug Administration to withdraw its approval of the product and demand it be pulled from the market after a confirmatory trial couldn’t replicate the results of a key study.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
APRIL 22, 2024
Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.
STAT
APRIL 22, 2024
WASHINGTON — Biden officials are still pressing to shore up abortion protections amid an onslaught of legal challenges, one of which is slated for Supreme Court arguments this week. The Department of Health and Human Services on Monday released a final rule that would put abortion services under the same federal privacy protections as other health care data covered by the Health Insurance Portability and Accountability Act, or HIPAA.
Fierce Healthcare
APRIL 22, 2024
UnitedHealth Group provided an update late Monday on its analysis of the data accessed in the cyberattack on Change Healthcare, and said it identified files that contain personal and health informa | UnitedHealth Group provided an update late Monday on its analysis of the data accessed in the cyberattack on Change Healthcare, and said it identified files that contain personal and health information.
STAT
APRIL 22, 2024
In human biology, the protein dystrophin is a shining example of Joni Mitchell’s classic line, “you don’t know what you’ve got ’til it’s gone.” Dystrophin stabilizes muscle cells. In its absence, the house of cards comes down. For my 6-year-old son, Charlie, dystrophin will govern how long he lives. And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
APRIL 22, 2024
Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.
STAT
APRIL 22, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Embracing Wall Street, stiff-arming Congress (for now) We finally got an answer of how much financial damage the Change Healthcare cyberattack did to UnitedHealth Group: Basically none.
Pharmacy Times
APRIL 22, 2024
Investigators found that 89% of individuals with cardiovascular disease consumed more than 1500 mg of sodium daily.
Fierce Healthcare
APRIL 22, 2024
Headspace has launched direct-to-consumer text-based mental health coaching to expand its reach beyond employer customers and capture the cash-pay healthcare market. | Headspace is entering the direct-to-consumer mental health coaching market, broadening its reach beyond its model of contracting with health plans and employers.
Drug Topics
APRIL 22, 2024
A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.
Fierce Healthcare
APRIL 22, 2024
The Biden administration will finalize a controversial nursing home staffing rule today that includes the more stringent requirements floated in last September’s proposal, Vice President Kamala Har | Later today the federal government will finalize the more stringent version of the Nursing Home Minimum Staffing rule floated last year, Vice President Kamala Harris' office said Monday morning.
Fierce Pharma
APRIL 22, 2024
The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. | The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. Supreme Court shot down the company’s attempt to challenge an appeals court decision invalidating several of the drug’s patents in 2023.
pharmaphorum
APRIL 22, 2024
Discover the innovative use of artificial intelligence (AI) in drug discovery with a focus on GenAI and Large Language Models (LLMs) on Day Two of this informative event. Explore how technology is revolutionising the pharmaceutical industry.
STAT
APRIL 22, 2024
The federal government is for the first time requiring nursing homes to have minimum staffing levels after the Covid-19 pandemic exposed grim realities in poorly staffed facilities for older and disabled Americans. Vice President Kamala Harris announced the final rules on Monday before a trip to La Crosse, Wis., where she will talk to nursing home care employees about their work.
pharmaphorum
APRIL 22, 2024
Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials. TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.
Fierce Pharma
APRIL 22, 2024
Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (rani | Sanofi will pay approximately $25,000 per person to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer, Bloomberg reported.
Fierce Healthcare
APRIL 22, 2024
A Seattle jury determined that Providence had underpaid thousands of its hourly employees by denying second meal breaks during long shifts and rounding down the minutes they clocked in for a shift. | A verdict reached last week could see up to $220 million paid out to over 33,000 of the system's hourly employees. Providence said it plans to appeal the decision.
Fierce Pharma
APRIL 22, 2024
After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. | After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. approval in the cancer immunotherapy Anktiva.
Pharmaceutical Technology
APRIL 22, 2024
Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.
STAT
APRIL 22, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation.
Pharmacy Times
APRIL 22, 2024
Sharing data and a personal recommendation can make a difference in a patient’s life
STAT
APRIL 22, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Hope you had a delightful weekend. Up today: an exclusive look at the scientific mix-up behind the approval of preterm birth drug Makena. We hear from a mother of a son with Duchenne muscular dystrophy who wants to ensure the FDA’s accelerated approval pathway stays strong, and more.
Pharmaceutical Technology
APRIL 22, 2024
Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.
Fierce Pharma
APRIL 22, 2024
As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) is expected in a few weeks, experts suggested the RNA si | As an all-important readout from Alnylam’s Amvuttra in the rare heart disease ATTR-CM is expected in a few weeks, experts suggested that the RNA silencer may have a hard time challenging Pfizer’s tafamidis franchise despite a last-minute trial design change.
European Pharmaceutical Review
APRIL 22, 2024
The USP Microbiology Expert Committee is due to vote on the proposed Chapter <86> to approve bacterial endotoxin testing using non-animal derived reagents between 21 June and 1 July 2024. Jaap Venema , Chief Science Officer, USP shared with EPR that the chapter is helping to guide manufacturers how to the adopt these methods and provides “a path to wider adoption”.
Expert insights. Personalized for you.
186 
Let's personalize your content